Rhythm Pharmaceuticals Inc [RYTM] stock is trading at $54.96, up 17.06%. An important factor to consider is whether the stock is rising or falling in short-term value. The RYTM shares have gain 3.76% over the last week, with a monthly amount glided 8.21%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Rhythm Pharmaceuticals Inc [NASDAQ: RYTM] stock has seen the most recent analyst activity on April 07, 2025, when BofA Securities upgraded its rating to a Buy but kept the price target unchanged to $63 for it. On January 02, 2025, Jefferies initiated with a Buy rating and assigned a price target of $80 on the stock. Oppenheimer started tracking the stock assigning a Outperform rating and suggested a price target of $76 on December 20, 2024. Guggenheim initiated its recommendation with a Buy and recommended $70 as its price target on October 21, 2024. H.C. Wainwright started tracking with a Buy rating for this stock on September 18, 2024, and assigned it a price target of $64. In a note dated September 17, 2024, JMP Securities initiated an Mkt Outperform rating and provided a target price of $64 on this stock.
Rhythm Pharmaceuticals Inc [RYTM] stock has fluctuated between $35.17 and $68.58 over the past year. Currently, Wall Street analysts expect the stock to reach $71.6 within the next 12 months. Rhythm Pharmaceuticals Inc [NASDAQ: RYTM] shares were valued at $54.96 at the most recent close of the market. An investor can expect a potential return of 30.28% based on the average RYTM price forecast.
Analyzing the RYTM fundamentals
Rhythm Pharmaceuticals Inc [NASDAQ:RYTM] reported sales of 130.13M for the trailing twelve months, which represents a growth of 72.61%. Gross Profit Margin for this corporation currently stands at 0.89% with Operating Profit Margin at -2.04%, Pretax Profit Margin comes in at -2.0%, and Net Profit Margin reading is -2.01%. To continue investigating profitability, this company’s Return on Assets is posted at -0.67, Equity is -3.79 and Total Capital is -0.96. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.02.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 48.61 points at the first support level, and at 42.25 for the second support level. However, for the 1st resistance point, the stock is sitting at 58.61, and for the 2nd resistance point, it is at 62.25.
Ratios To Look Out For
For context, Rhythm Pharmaceuticals Inc’s Current Ratio is 3.24. On the other hand, the Quick Ratio is 3.08, and the Cash Ratio is 0.77. Considering the valuation of this stock, the price to sales ratio is 26.70, the price to book ratio is 157.81.
Transactions by insiders
Recent insider trading involved German Christopher Paul, Corporate Controller & CAO, that happened on Mar 21 ’25 when 344.0 shares were sold. EVP, Head of International, Mazabraud Yann completed a deal on Mar 14 ’25 to sell 75000.0 shares. Meanwhile, Officer YANN MAZZABRAUD bought 75000.0 shares on Mar 14 ’25.
